Abstract
Purpose :
We attempted to investigate the hypothesis that the co-transplanted mesenchymal stem cells (MSCs) would augment the therapeutic efficacy of induced pluripotent stem cell-derived corneal endothelial cells (iPSC-CECs) and enhance survival by reducing the immunological rejection of iPSC-CECs in a rabbit model of corneal endothelial dysfunction.
Methods :
We made a rabbit model of corneal endothelial dysfunction by Descemet’s membrane stripping. Rabbits were divided into four groups according to the injected cells after stripping: control (PBS), MSCs, iPSC-CECs, and a combination of both MSCs and iPSC-CECs. We observed anterior segment photography, and monitored intraocular pressure of all rabbits weekly up to 6 weeks. After 6 weeks, we sacrificed all rabbits and examined the anterior segment optical coherence tomography and histologic findings.
Results :
We successfully created a rabbit model of corneal endothelial dysfunction in all twelve rabbits. The co-transplantation of iPSC-CECs and MSCs promoted corneal endothelial regeneration with increased corneal transparency compared to MSC or iPSC-CECs components alone through suppressing inflammation, inhibiting angiogenesis, promoting cell proliferation, and enhancing pump function.
Conclusions :
In conclusion, the co-transplantation of MSCs might control immune rejection against iPSC-CEC after in vivo transplantation; thus, this comprises a promising strategy for regenerating corneal endothelial using iPSC-CECs and MSCs than their individual components, supporting further translation to larger animal models and human subjects.
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.